Characterizing ART-free NK cell-mediated control of HIV infection in people living with HIV

描述 HIV 感染者中无 ART 的 NK 细胞介导的 HIV 感染控制

基本信息

  • 批准号:
    10671559
  • 负责人:
  • 金额:
    $ 23.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY People living with HIV (PLWH) can be treated effectively with antiretroviral therapy (ART) but for most, as soon as ART is stopped, HIV quickly rebounds within weeks. However, in rare individuals, called post-treatment controllers (PTCs), HIV is controlled by immune-mediated mechanisms and viral rebound is suppressed. How this occurs remains poorly understood. One type of immune cell in PTCs that has been implicated in viral control during ART interruption is Natural Killer (NK) cells. These cells can rapidly respond to and kill infected cells as part of a classical innate immune response, but more recently has also been suggested to be capable of harboring “memory” against prior infection including that by HIV. This “memory” is thought to be in part mediated through epigenetic mechanisms. The types and features of NK cells in PTCs, and whether they differ from those in non-controllers (NCs), is not known. A better understanding of these cells is the first step towards understanding how they can control HIV and be harnessed for therapy. The objective of this proposal is to deeply characterize the features and effector functions of NK cells in PTCs and non-controllers (NCs), and to identify biomarkers on NK cells prior to analytical treatment interruption (ATI) that predict HIV remission. We hypothesize that NK cells, including memory NK cell subsets, help to control HIV after ART is removed in PTCs. We will use longitudinal samples from clinically-matched PTCs and NCs from the CHAMP study, sampled ATI, and at early (within 12 weeks) and late (after 24 weeks) timepoints after ATI. In Aim 1, we will use mass cytometry (CyTOF) to determine the phenotypes and effector functions of NK cell subsets from PTCs and NCs before and after ATI. In Aim 2, we will use multiplexed single-cell RNAseq and single-cell ATACseq to identify transcriptional and epigenetic signatures of memory and non-memory NK cells from PTCs vs. NCs after treatment interruption. Understanding immune responses capable of mediating HIV remission provides an avenue for development of novel therapeutics to cure HIV. Equally essential are non-invasive biomarker(s) that predict HIV remission for safer treatment interruption trials. This proposal addresses both these aspects focusing specifically on NK cells, powerful immune effectors that are much understudied with regards to their potential to mediate HIV remission.
项目摘要 患有艾滋病毒(PLWH)的人可以通过抗逆转录病毒疗法(ART)进行有效治疗,但对于大多数人来说 随着艺术的停止,艾滋病毒和篮板在几周内。 控制器(PTC),HIV受到免疫介导的机制控制,病毒反弹被抑制。 这种情况仍然很少了解。 在ART中断期间,自然杀手(NK)细胞可以迅速响应并杀死感染细胞 经典先天免疫反应的一部分,但最近也被认为有能力 在包括艾滋病毒(艾滋病毒)的“记忆”中携带“记忆”。 通过表观遗传机制。 在非控制器(NCS)中,尚不清楚。 了解如何控制艾滋病毒并利用治疗的目的。 深层表征PTC和非控制器(NCS)中NK细胞的功能和效应子功能,并 在分析治疗中断(ATI)之前,在NK细胞上识别生物标志物 假设NK细胞(包含记忆NK细胞子集)有助于控制ART在PTC中的ART后控制HIV。 我们。 在AIM 1中的ATI之后,在12周内(12周内)和晚期(24周后) (cytof)确定来自PTC和NCS的NK细胞子集的表型和效应功能 ATI在AIM 2中,我们将多重的单细胞RNASEQ和单细胞ATACSEQ识别转录 在PTCS中,NC的记忆和记忆NK细胞的表观遗传签名。 了解能够调解艾滋病毒改造的免疫反应为发展提供了开发的途径 治愈艾滋病毒的新型治疗方法是无创的生物标志物 更安全的治疗中断试验。 强大的免疫效应子对介导HIV缓解的潜力被低估了。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nadia R Roan其他文献

Nadia R Roan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nadia R Roan', 18)}}的其他基金

Reservoir features associated with time-to-rebound during analytical treatment interruption
与分析处理中断期间的反弹时间相关的储层特征
  • 批准号:
    10459934
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
Characterizing ART-free NK cell-mediated control of HIV infection in people living with HIV
描述 HIV 感染者中无 ART 的 NK 细胞介导的 HIV 感染控制
  • 批准号:
    10535192
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
Reservoir features associated with time-to-rebound during analytical treatment interruption
与分析处理中断期间的反弹时间相关的储层特征
  • 批准号:
    10614027
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies
通过单细胞技术对体内 HIV 潜伏病毒库进行表型和机制分析
  • 批准号:
    10357547
  • 财政年份:
    2019
  • 资助金额:
    $ 23.63万
  • 项目类别:
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies
通过单细胞技术对体内 HIV 潜伏病毒库进行表型和机制分析
  • 批准号:
    10448398
  • 财政年份:
    2019
  • 资助金额:
    $ 23.63万
  • 项目类别:
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies
通过单细胞技术对体内 HIV 潜伏病毒库进行表型和机制分析
  • 批准号:
    10360854
  • 财政年份:
    2019
  • 资助金额:
    $ 23.63万
  • 项目类别:
Project 1: Using CyTOF to identify phenotypic and functional biomarkers predicting time to HIV rebound after treatment interruption
项目 1:使用 CyTOF 识别表型和功能生物标志物,预测治疗中断后 HIV 反弹的时间
  • 批准号:
    10223995
  • 财政年份:
    2017
  • 资助金额:
    $ 23.63万
  • 项目类别:
Exploiting the Host-HIV Interface To Identify Biomarkers Predicting Time to Viral Rebound after Treatment Interruption
利用宿主-HIV 界面识别生物标志物,预测治疗中断后病毒反弹的时间
  • 批准号:
    10223991
  • 财政年份:
    2017
  • 资助金额:
    $ 23.63万
  • 项目类别:
Characterization of Exosomes From Semen of Uninfected and HIV-Infected Men
未感染和 HIV 感染男性精液中外泌体的表征
  • 批准号:
    9228315
  • 财政年份:
    2016
  • 资助金额:
    $ 23.63万
  • 项目类别:
Characterization of Exosomes From Semen of Uninfected and HIV-Infected Men
未感染和 HIV 感染男性精液中外泌体的表征
  • 批准号:
    9062790
  • 财政年份:
    2016
  • 资助金额:
    $ 23.63万
  • 项目类别:

相似国自然基金

淋巴因子激活之自然杀伤细胞抗肿瘤肺转移的高功效研究
  • 批准号:
    38970343
  • 批准年份:
    1989
  • 资助金额:
    4.0 万元
  • 项目类别:
    面上项目

相似海外基金

Selective targeting of a Rho GTPase mutant for peripheral T cell lymphoma treatment
选择性靶向 Rho GTPase 突变体治疗外周 T 细胞淋巴瘤
  • 批准号:
    10721439
  • 财政年份:
    2023
  • 资助金额:
    $ 23.63万
  • 项目类别:
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
  • 批准号:
    10911713
  • 财政年份:
    2023
  • 资助金额:
    $ 23.63万
  • 项目类别:
Pathways modulating memory-like properties in NK cells and their impact on HIV control
调节 NK 细胞记忆样特性的途径及其对 HIV 控制的影响
  • 批准号:
    10534402
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
Mechanisms underlying combination therapy mobilizing NK cells
联合治疗动员 NK 细胞的机制
  • 批准号:
    10623188
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
Directing Cytokine Specificity Through Co-translational Carrier Coupling
通过共翻译载体偶联指导细胞因子特异性
  • 批准号:
    10581947
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了